This is the collection of Archive posts.

Hematologic Malignancies

Vanda-VTR-297-1101-A Phase I multicenter, open label, dose-escalation study to determine the maximum tolerated does for Trichostatin A in subjects with replapsed or refractory Hematologic Malignancies. Adagene Inc.-ADG106-A Study of CD137… Read More

Epithelial Tumors

PSI Oxus- ColoAD 1003-Phase 1 multicentre, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors. Read More

Solid Tumors

Altor Bioscience-QUILT-3.055: A Phase 2b, Single-Arm, Multicohort, Open-Label Study of ALT-803 in Combination with a PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Have Disease Progression Following an Initial Response to Treatment… Read More


LAM Therapeutics-LAM-002A-NHL-CLN01-A Phase 1 dose escalation study of the safety and pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) administered orally in subjects with relapsed or refractory B-Cell Non-Hodgkin’s Lymphoma I-MAB Biopharma,… Read More